Apply Of Pegylated Liposomal Doxorubicin In Diffuse Large B Cell Lymphoma And Clinical Analysis Of Tolerability And Curative Effect

Objective:To evaluate the curative effect and tolerability of DRCOP regimen that consists of pegylated liposomal doxorubicin in diffuse large B cell lymphoma,compared to RCHOP regimen that consists of epirubicin or pirarubicin,to explore curative effect and tolerability in DLBCL with different clinical characteristics,and to provide evidence for establishment of clinical stratified strategy.Method:We performed a retrospective analysis of 35 and 37 DLBCL patients who received DRCOP regimen chemotherapy and RCHOP regimen chemotherapy respectively from 2015.1 to 2016.10 in The First Affiliated Hospital of Zhejiang University.Describing their clinical characteristic and long-term survival,analyse the influence of factors including age,course of disease,disease status,associated disease,etc to hepatorenal function,cardiac function,complete remission rate,overall survival and progression-free survival.Results:The complete remission rate,2-year overall survival rate,and 2-year progression-free survival are 62.9%,and 64.9%respectively,67.9%,and 70.1%respectively,57.2%,and 41.0%respectively in receiving DRCOP regimen chemotherapy and RCHOP regimen chemotherapy with no statistically significant difference between two regimen.In the analysis of tolerability,there is no statistically significant variability of hepatorenal function,and cardiac function after receiving DRCOP regimen chemotherapy in young patients,elderly patients,and patients associated with cardiocerebrovascular diseases.There is no statistically significant variability of hepatorenal function but statistically significant(P=0.049)variability of ratio of early diastolic velocity of mitral valve(E)and late peak speed(A),which can evaluate left ventricular diastolic function after receiving RCHOP regimen chemotherapy,in young patients,elderly patients,and patients associated with cardiocerebrovascular diseases.Then we continued to discovered that the decrease of E/A ratio is statistically significant after receiving RCHOP regimen chemotherapy in elderly patient and elderly patients associated with cardiocerebrovascular diseases(P=0.006,P=0.023).Conclusion:The curative effect of RCHOP regimen is the same as RCHOP regimen in DLBCL.It’s suitable for elderly DLBCL patient especially associated with cardiocerebrovascular diseases receiving DRCOP regimen chemotherapy。As to young patient LPD can be chosen instead of other anthracyclines to decrease the incidence of chronic and delayed cardiac toxicity.